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Abstract 
Background: Radiotherapy is one of the main therapeutic approaches for non–small cell lung cancer (NSCLC). 
However, radioresistant cancer cells can eventually cause tumor relapse and even fatal metastasis. It is thought that 
radioresistance and metastasis could be potentially linked by epithelial‑mesenchymal transition (EMT). In this study, 
we established radioresistant NSCLC cells to investigate the potential relationship among radioresistance, EMT, and 
enhanced metastatic potential and the underlying mechanism involving liver kinase B1 (LKB1)‑Salt‑inducible kinase 1 
(SIK1) signaling.
Methods: The radioresistant cell lines A549R and H1299R were generated by dose‑gradient irradiation of the paren‑
tal A549 and H1299 cells. The radioresistance/sensitivity was evaluated by Cell Counting Kit‑8 assay, apoptosis analysis, 
and/or clonogenic cell survival assay. The EMT phenotype and the signaling change were assessed by Western blot‑
ting. The abilities of invasion and migration were evaluated by transwell assays and wound healing assays.
Results: The radioresistant cell lines A549R and H1299R displayed mesenchymal features with enhanced invasion 
and migration. Mechanistically, A549R and H1299R cells had attenuated LKB1‑SIK1 signaling, which leaded to the 
up‑regulation of Zinc‑finger E‑box‑binding homeobox factor 1 (ZEB1)—a transcription factor that drives EMT. Re‑
expression of LKB1 in A549R cells reversed the EMT phenotype, whereas knockdown of LKB1 in H1299R cells further 
promoted the EMT phenotype. Moreover, re‑expression of LKB1 in A549 cells increased the radiosensitivity, whereas 
knockdown of LKB1 in H1299 cells decreased the radiosensitivity.
Conclusions: Our findings suggest that attenuated LKB1‑SIK1 signaling promotes EMT and radioresistance of NSCLC 
cells, which subsequently contributes to the enhanced metastatic potential. Targeting the LKB1‑SIK1‑ZEB1 pathway to 
suppress EMT might provide therapeutic benefits.
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Background
Lung cancer is a leading cause of cancer-related death 
worldwide [1] and in China [2]. According to a statistic 
of the major cancers in China, 2011, lung cancer had 
the highest incidence in males and the second highest 
incidence in females, and it accounted for 27.08% and 
25.08% of all cancer deaths in males and females, respec-
tively [2].
Radiotherapy is a common treatment of lung cancer; 
despite advances in radiation technology, its efficacy is lim-
ited, and the prognosis of patients with lung cancer remains 
poor [3]. After definitive radiotherapy, up to one-third of 
patients will have local recurrence and distant metastasis 
[3]. Radioresistant cancer cells likely play a crucial role in the 
recurrence and metastasis of lung cancer after radiotherapy. 
Open Access
Chinese Journal of Cancer
*Correspondence:  yujinmingsdjn@126.com 
6 Department of Radiation Oncology, Shandong Cancer Hospital 
and Institute, Shandong University, Jinan 250117, Shandong, P. R. China
Full list of author information is available at the end of the article
Page 2 of 9Yao et al. Chin J Cancer  (2016) 35:50 
Several studies suggested that radioresistant cancer cells 
have enhanced invasion and metastasis potential [4, 5].
Epithelial-mesenchymal transition (EMT) is a complex 
process accompanied by loss of epithelial markers such 
as E-cadherin and acquisition of mesenchymal mark-
ers such as vimentin and fibronectin [6]. During EMT, 
epithelial cells lose cell-cell contacts and apical-basal 
polarity and acquire migratory properties [7]. Emerging 
evidence suggests that EMT is a key step toward cancer 
metastasis and is associated with radioresistance [8]. 
It has been reported that in  vitro cultured lung cancer 
cells that survived ionizing radiation treatment display 
the EMT phenotype and have increased invasion abil-
ity [9]. More importantly, it has also been observed that 
radiotherapy may induce EMT in vivo, demonstrated by 
comparing surgically resected non–small cell lung cancer 
(NSCLC) specimens before and after radiotherapy [10].
Liver kinase B1 (LKB1), also known as serine/threo-
nine protein kinase 11 (STK11), functions in many types 
of cancer as a tumor suppressor. Particularly, LKB1 is the 
third most commonly mutated gene in lung adenocarci-
noma [11]. Retrospective studies of patient cohorts sug-
gest that LKB1 expression is negatively associated with 
lymph node metastasis [12, 13]. Using the mouse model 
of oncogenic Kras-driven lung cancer, LKB1 has been 
shown to be a critical barrier to lung cancer initiation 
and metastasis [14]. LKB1 directly phosphorylates and 
activates 5′-adenosine monophosphate-activated pro-
tein kinase (AMPK) and AMPK-related kinases to con-
trol cell metabolism, proliferation, and polarity, which at 
least partly accounts for its tumor suppressor function 
[15, 16]. Salt-inducible kinase 1 (SIK1) is a member of the 
AMPK-related kinase family and is also a critical effector 
of LKB1 to suppress metastasis [17]. It has been shown 
that LKB1-SIK1 signaling suppresses EMT by repressing 
the expression of several transcriptional factors critically 
involved in EMT, including snail2, twist, and Zinc-finger 
E-box-binding homeobox factor 1 (ZEB1) [18].
In this study, we established radioresistant NSCLC cells 
lines A549R and H1299R and investigated the potential 
relationship among radioresistance, EMT, and enhanced 
metastatic potential and the underlying mechanism 
involving LKB1-SIK1 signaling.
Methods
Cell lines and culture conditions
Human lung cancer cell lines A549 and H1299 were pur-
chased from Keygen Biotech (Nanjing, China). The radi-
oresistant derivatives A549R and H1299R were generated 
by dose-gradient irradiation of the parental cells. All cells 
were maintained in RPMI-1640 medium (Gibco, New 
York, MD, USA) containing 10% fetal bovine serum at 
37°C with 5% CO2 in a humidified incubator.
Dose‑gradient irradiation
Irradiation was performed at a dose rate of 300 cGy/min 
at room temperature using a Varian 23 EX Clinac lin-
ear accelerator (Varian Medical Systems, Inc., Palo Alto, 
CA, USA). For the first irradiation, A549 and H1299 
cells were grown to 60%–70% confluence and irradiated 
with 2 Gy of X-ray; the culture medium was replenished 
immediately after irradiation. When the cells reached the 
confluence of more than 80%, they were trypsinized and 
passaged. After two passages, the same irradiation and 
cell propagation procedure was performed. The proce-
dure was further repeated with gradually increased radia-
tion dose, and each dose was used twice. In total, the cells 
received 60 Gy of radiation (2 × 2 Gy, 2 × 4 Gy, 2 × 6 Gy, 
2 × 8 Gy, and 2 × 10 Gy). The surviving cells were propa-
gated and passaged for five or more generations before 
being used for other experiments.
Cell viability/proliferation assay with Cell Counting Kit‑8
A Cell Counting Kit-8 (CCK-8) kit (Dojindo Laborato-
ries, Kumamoto, Japan) was used to determine cell via-
bility and proliferation after irradiation. Briefly, the cells 
were seeded in a 96-well plate (3000 cells/well, four rep-
licates for each cell line) and incubated overnight. The 
cells were irradiated with five different doses (0, 2, 4, 6, 
and 8 Gy) and then incubated for further 48 h. The cells 
were replenished with a medium containing CCK-8 solu-
tion (10 μL CCK-8 in 100 μL medium) and incubated for 
another 2  h; then the absorbance at 450  nm was meas-
ured using a microplate reader (Bio-Tek Instruments, 
Winooski, VT, USA). The survival rate of cells was calcu-
lated as the normalized absorbance to the non-irradiated 
controls.
Apoptosis detection
Cells were stained with an Annexin V-FITC detection kit 
(KeyGen, Nanjing, Jiangsu, China), following the manu-
facturer’s instructions, and analyzed with a BD FACScan 
system (BD Biosciences, San Jose, CA, USA). The graph 
was plotted using Flowjo 7.6.5 software (FLOWJO LLC, 
Ashland, KY, USA).
Plasmids and transfections
The pEGFP-LKB1, pEGFP-Ctrl, pshLKB1, and pshCtrl 
plasmids were constructed by GenePharma (Shanghai, 
China). Human LKB1 open reading frame was inserted 
in-frame with enhanced green fluorescent protein 
(EGFP) into the pEGFP-N1 vector to obtain the pEGFP-
LKB1 vector. pGenesil-1 is a derivative of the pEGFP-C1 
vector, which contains a human U6 promoter to drive 
short hairpin RNA (shRNA) expression. A DNA frag-
ment encoding an shRNA against human LKB1 was 
inserted into the pGenesil-1 vector to obtain pshLKB1; 
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the scrambled shRNA was also cloned into pGenesil-1 
to obtain pshCtrl. The target sequence of LKB1 was 
5′-GGTACTTCTGTCAGCTGATTG-3′, and the scram-
bled shRNA sequence was 5′-GTTCTCCGAACGT-
GTCACGTT-3′. Transient transfection was performed 
with Lipofectamine 2000 (Invitrogen, Shanghai, China), 
following the manufacturer’s instructions. Twenty-four 
hours after transfection, the cells were harvested for 
either Western blot analysis or further functional tests.
Western blotting and antibodies
Western blotting was performed as described previously 
[19]. The following primary antibodies were used: LKB1 
(ab15095, 1:100) from Abcam (Cambridge, UK); E-cad-
herin (BS1097, 1:500), vimentin (BS1776, 1:500), β-actin 
(BS6007 M, 1:10,000), p-CHK2 (p-T68) (BS4043, 1:500), 
and γ-H2AX (p-S139) (BS4760, 1:500) from Bioworld 
Technology (Nanjing, Jiangsu, China); and SIK1 (51045-
1-AP, 1:1000) and ZEB1 (21544-1-AP, 1:1000) from Pro-
teintech Group (Wuhan, Hubei, China). All primary 
antibodies were incubated with the blot at 4°C over-
night. The signals were detected with an Odyssey Infra-
red Imaging system (LI-COR, Lincoln, NE, USA). For 
quantification of the protein levels, the intensity of each 
strip was analyzed by Image J software (NIH, Bethesda, 
MD, USA). The average intensities of the proteins were 
normalized to β-actin. The relative protein levels are pre-
sented as mean ± standard deviation (SD).
Cell invasion assay
Invasion ability of the cells was determined using a 
modified two-chamber plate with a pore size of 8  μm. 
The transwell filter inserts were coated with Matrigel 
(BD Biosciences, New York, NJ, USA), and 5 × 104 cells 
were seeded in serum-free medium in the upper cham-
ber. After incubation for 48 h at 37°C, cells in the upper 
chamber were carefully removed with a cotton swab, and 
the cells that had traversed the membrane were fixed 
in methanol and stained with crystal violet. The cells 
were counted under an inverted microscope and photo-
graphed. If transient transfection was performed prior to 
the assay, the cells were seeded 24 h after the transfection.
Cell migration assay
Migration assay was performed similarly to the invasion 
assay, with the following differences: the transwell filter 
inserts were not coated; 3 ×  104 cells were seeded; and 
the incubation time was 24 h before fixation.
Wound healing assay
A wound was made by dragging a yellow pipette tip along 
the center of the plate. The distance between the cells 
bordering the wound was measured after 24  h. Images 
were taken with a digital camera under a phase-contrast 
microscope. If transient transfection was performed 
prior to the assay, the cells were wounded 24 h after the 
transfection.
Clonogenic cell survival assay
The cells were seeded in six-well plates (200, 400, 1000, 
3000, and 5000 cells/well in triplicate, corresponding to 
the radiation dose of 0, 2, 4, 6, and 8  Gy, respectively). 
After overnight incubation, the cells were irradiated with 
the respective dose. The medium was replenished after 
the irradiation, and the cells were cultured for 14  days 
prior to formaldehyde fixation and crystal violet stain-
ing. The colonies with 50 or more cells were counted. The 
plating efficiency was calculated as the ratio of the colo-
nies number to the plated cell number. The survival frac-
tion was calculated as the normalized plating efficiency 
to the non-irradiated controls. Using GraphPad Prism 
5.0 software (GraphPad Software, La Jolla, CA, USA), the 
survival curves were fitted to a linear-quadratic model to 
estimate the sensitizer enhancement ratio.
Statistical analysis
All statistical analyses were performed by using SPSS 
version 16.0 software (IBM, Chicago, IL, USA) except 
for those specially stated. All values are shown as 
mean ± SD. Student’s t test and one-way analysis of vari-
ance (ANOVA) were used to evaluate significance. P val-
ues less than 0.05 were considered statistically significant. 
All tests were two-tailed.
Results
Radioresistant A549R and H1299R cells displayed the EMT 
phenotype
By dose-gradient irradiation of the parental A549 and 
H1299 cells to the total dose of 60  Gy, we derived the 
respective radioresistant cell lines A549R and H1299R. 
Compared with the parental cells, A549R and H1299R 
demonstrated a significantly increased survival rate 
and reduced apoptosis after ionizing radiation (Fig.  1), 
supporting the hypothesis that these cells were more 
resistant to radiation. A549R and H1299R cells showed 
enlarged size and mesenchymal morphology indicative 
of EMT (Fig.  2a). Examination of the epithelial marker 
E-cadherin and the mesenchymal marker vimentin by 
Western blotting confirmed dramatic down-regulation of 
E-cadherin and concomitant up-regulation of vimentin in 
A549R and H1299R cells (Fig. 2b, c). These observations 
suggest that A549R and H1299R cells underwent EMT. 
EMT was likely induced gradually during the dose-gra-
dient irradiation procedure. Therefore, we examined the 
dynamic change of E-cadherin and vimentin expression. 
Indeed, only when the radiation dose was accumulated to 
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60 Gy was the expression level of E-cadherin and vimen-
tin significantly changed (Fig.  2d, e). The DNA damage 
response was also gradually induced during the accumu-
lation of radiation, indicated by the increased phospho-
rylation of Chk2 (p-T68) and γ-H2AX (Fig. 2d, e).
A549R and H1299R cells showed enhanced ability 
of invasion and migration
Since EMT is closely related to metastasis [7], we next 
tested the ability of invasion and migration of the cells. As 
expected, by transwell assays, A549R and H1299R cells 
showed enhanced ability of invasion and migration com-
pared with the parental cells (Fig.  3a, b). Wound heal-
ing assay by in vitro scratch method also supported the 
hypothesis that A549R and H1299R cells had increased 
migratory ability (Fig. 3c, d).
A549R and H1299R cells had attenuated LKB1‑SIK1 
signaling and up‑regulation of ZEB1
LKB1 is a tumor suppressor that is frequently inactivated 
in lung adenocarcinoma [11]. LKB1 phosphorylates and 
activates SIK1 to repress the expression of ZEB1 [18], 
and ZEB1 is a potent driver of EMT [6]. We next tested 
whether this pathway is dysregulated in A549R and 
H1299R cells. It has been reported that A549 cells have 
no expression of LKB1, whereas H1299 cells express 
wild-type LKB1 [20]. Indeed, LKB1 expression was 
clearly detected in H1299 cells but not in A549 cells 
(Fig.  4a, b). Interestingly, in H1299R cells, we found a 
dramatically reduced expression of LKB1 and SIK1 and 
increased expression of ZEB1. In A549R cells, we also 
observed reduced expression of SIK1 and increased 
expression of ZEB1, despite LKB1 not being expressed. 
This result suggested that dysregulation of the LKB1-
SIK1-ZEB1 pathway was common in both A549R and 
H1299R cells, although it occurred at different levels due 
to different genetic backgrounds.
LKB1‑SIK1 signaling suppressed the EMT phenotype 
of A549R and H1299R cells
To examine LKB1’s effect on the SIK1-ZEB1 signal-
ing and the EMT phenotype, we manipulated the 
Fig. 1 A549R and H1299R cells were more resistant to ionizing radiation than the parental A549 and H1299 cells. a The cells were irradiated with 
the indicated dose; 48 h later, Cell Counting Kit‑8 assay was performed to detect the viability and proliferation of the cells. The survival rate was nor‑
malized to the non‑irradiated controls. *P < 0.05 (Student’s t test). b The cells were irradiated with 2 Gy of X‑ray; 24 h later, the apoptosis of the cells 
was determined by Annexin V‑FITC/propidium iodide (PI) staining and fluorescence‑activated cell sorting analysis. Representative results are shown. 
The apoptotic fraction (Q2 + Q4) from three independent experiments was used to plot the bar chart. *P < 0.05 (Student’s t test)
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expression level of LKB1 by transient transfection of 
vectors encoding either EGFP-LKB1 or an shRNA 
against LKB1. Re-expression of LKB1 in A549R cells 
caused increased expression of SIK1 and decreased 
expression of ZEB1 (Fig.  4c, d). Importantly, it also 
caused markedly increased expression of E-cadherin and 
decreased expression of vimentin, suggesting a rever-
sal of EMT. On the other hand, knockdown of LKB1 in 
H1299R cells caused decreased expression of SIK1 and 
increased expression of ZEB1 and exacerbated the EMT 
phenotype. Together, our data suggest that LKB1-SIK1 
signaling suppresses the EMT phenotype, and that dys-
regulation of the LKB1-SIK1-ZEB1 pathway may play 
a causative role in the EMT phenotype of A549R and 
H1299R cells.
LKB1 suppressed the invasion and migration of A549R 
and H1299R cells
Since LKB1 signaling was negatively associated with the 
EMT phenotype of A549R and H1299R cells, we then 
tested whether this could translate into metastatic behav-
ior. Re-expression of LKB1 in A549R cells decreased 
the number of cells invaded or migrated into the lower 
chamber of the transwell, whereas knockdown of LKB1 
in H1299R cells demonstrated the opposite effect 
(Fig. 5a, b). Wound healing assay also showed that LKB1 
suppressed the migration of A549R and H1299R cells 
(Fig.  5c, d). However, we also observed that re-expres-
sion of LKB1 inhibited the proliferation of A549R cells, 
whereas knockdown of LKB1 promoted the prolifera-
tion of H1299R cells (data not shown). To minimize the 
Fig. 2 The radioresistant non‑small cell lung cancer cells displayed the epithelial–mesenchymal transition phenotype. a The cells were photo‑
graphed by light microscope at ×100 magnification. b Western blot analysis of E‑cadherin and vimentin expression in A549, A549R, H1299, and 
H1299R cells. c The quantification of the protein levels in b **P < 0.01 (Student’s t test). d Western blot analysis of the dynamic change of the protein 
levels of E‑cadherin, vimentin, phosphor‑Chk2 (p‑Chk2), and γ‑H2AX during the accumulation of the radiation dose. e The quantification of the 
protein levels in d. *P < 0.05 (ANOVA‑SNK‑q′) versus the respective 0‑Gy group
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effect of different proliferation rates, we used serum-free 
medium in the transwell assays; we could not, however, 
exclude the effects of different proliferation rates on 
our results. Thus, the observed suppression of invasion 
and migration of A549R and H1299R cells by LKB1 was 
likely a combined effect that included the inhibition of 
proliferation.
LKB1 increased the radiosensitivity of A549 and H1299 
cells
Increasing evidence connects EMT and radioresistance 
[8]. Since LKB1-SIK1 signaling suppressed the EMT 
phenotype of A549R and H1299R cells as shown pre-
viously, an intriguing question is whether LKB1 could 
also increase the radiosensitivity. To address this ques-
tion, we either re-expressed or knocked down LKB1 in 
A549 or H1299 cells, respectively, and subjected the 
cells to radiation. Indeed, as assessed by clonogenic 
cell survival assay, re-expression of LKB1 increased 
the radiosensitivity of A549 cells, whereas knockdown 
of LKB1 decreased the radiosensitivity of H1299 cells 
(Fig. 6).
Discussion
Intrinsic and/or acquired resistance to radiotherapy has 
been recognized as a significant impediment to effective 
cancer treatment [21]. Evidence suggests that NSCLC 
cells that survive ionizing radiation treatment display 
cancer stem cell and EMT phenotypes [9]. In this study, 
two radioresistant NSCLC cell lines, A549R and H1299R, 
were established by dose-gradient irradiation of A549 
and H1299 cells. As expected, A549R and H1299R cells 
showed increased radioresistance. Consistent with the 
results of other studies, our findings suggest that radia-
tion induces the EMT phenotype with increased ability 
of invasion and migration.
The expression of LKB1 is frequently reduced in cer-
tain human cancers and is negatively associated with the 
outcome of lung cancer patients [22]. We found that the 
expression of LKB1 was dramatically reduced in H1299R 
cells compared with the parental cells. Although A549 cells 
did not express LKB1, the expression of SIK1 (a down-
stream effector of LKB1) was reduced in A549R cells. 
Therefore, the LKB1-SIK1 signaling was attenuated in both 
A549R and H1299R cells. This raises the possibility that 
Fig. 3 The radioresistant non‑small cell lung cancer cells showed enhanced ability of invasion and migration. a, b Transwell matrigel invasion and 
migration assays with A549, A549R, H1299, and H1299R cells. The cells were stained with crystal violet, counted under a light microscope, and 
photographed at 200× magnification. The cell number was normalized to A549 or H1299 cells, respectively, and are presented as mean ± standard 
deviation (SD). **P < 0.01 (Student’s t test). c, d Wound healing assay with A549, A549R, H1299, and H1299R cells. Representative pictures are shown, 
and the width of the wounds was measured at 0 and 24 h after the scratch. The migration rate was normalized to A549 or H1299 cells, respectively, 
and is presented as mean ± SD. **P < 0.01 (Student’s t test)
Page 7 of 9Yao et al. Chin J Cancer  (2016) 35:50 
Fig. 4 Liver kinase B1 (LKB1)‑salt‑inducible kinase 1 (SIK1) signaling suppressed the epithelial–mesenchymal transition phenotype of A549R and 
H1299R cells. a Western blot analysis of LKB1, SIK1, and Zinc‑finger E‑box‑binding homeobox factor 1 (ZEB1) expression in A549, A549R, H1299, 
and H1299R cells. b The quantification of the protein levels in a. *P < 0.05; **P < 0.01 (Student’s t test). c Western blot analysis of LKB1, SIK1, ZEB1, 
E‑cadherin, and vimentin expression in A549R cells transfected with enhanced green fluorescent protein (EGFP) or EGFP‑LKB1 (left panel), and 
H1299R cells transfected with shCtrl or shLKB1 (right panel). d The quantification of the protein levels in c. *P < 0.05; **P < 0.01 (Student’s t test)
Fig. 5 LKB1 suppressed the invasion and migration of A549R and H1299R cells. a, b Transwell matrigel invasion and migration assays with A549R 
cells transfected with EGFP or EGFP‑LKB1, and H1299R cells transfected with shCtrl or shLKB1. c, d Wound healing assay with A549R cells transfected 
with EGFP or EGFP‑LKB1, and H1299R cells transfected with shCtrl or shLKB1. The experimental procedure is described in Fig. 3, *P < 0.05; **P < 0.01 
(Student’s t test)
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reduced LKB1-SIK1 signaling may confer a survival advan-
tage during and after ionizing radiation. Indeed, we showed 
that LKB1-SIK1 signaling was negatively associated with 
the EMT phenotype and increased the radiosensitivity of 
A549 and H1299 cells. Suppression of EMT by LKB1-SIK1 
signaling is likely through repression of ZEB1, a potent 
driver of EMT; indeed, we observed a negative associa-
tion between ZEB1 expression and EMT. Taken together, 
our work stresses the importance of LKB1 signaling in the 
radiotherapy of NSCLC, since inactivation of this pathway 
promotes EMT, which not only contributes to radioresist-
ance but also increases the risk of metastasis. On the other 
hand, exploiting this pathway to suppress EMT might pro-
vide therapeutic benefits by increasing radiosensitivity and 
by reducing the risk of metastasis. EMT is also associated 
with resistance to chemotherapy [23]; thus, targeting the 
LKB1-SIK1-ZEB1 pathway to suppress EMT could have 
even broader therapeutic implications.
It is well known that matrix metalloproteinases (MMPs) 
play an important role in the invasion and metastasis of 
cancer cells by degrading the extracellular matrix [24]. 
MMPs are also closely related to EMT, since activation of 
the EMT process is dependent on MMPs, and overexpres-
sion of MMPs promotes EMT [24]. Interestingly, several 
studies reported that LKB1 can down-regulate the expres-
sion of MMP-2 and MMP-9 [25–27]. Further investiga-
tion is required to determine whether this is part of the 
mechanism by which LKB1 suppresses EMT.
Conclusions
Our findings suggest that attenuated LKB1-SIK1 signal-
ing promotes EMT and the radioresistance of NSCLC 
cells, which subsequently contributes to enhanced 
metastatic potential. Therefore, targeting the LKB1-
SIK1-ZEB1 pathway to suppress EMT might provide 
therapeutic benefits, not only by increasing the radiosen-
sitivity of the cancer cells but also by reducing the risk of 
metastasis after radiotherapy.
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